In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling

Neuropsychopharmacology

Volumn 29, Issue 3, 2004, Pages 514-521

  Wierońska, Joanna M ^a   Śmiałowska, Maria ^a   Brański, Piotr ^a   Gasparini, Fabrizio ^b   Kłodzińska, Aleksandra ^a   Szewczyk, Bernadeta ^a   Pałucha, Agnieszka ^a   Chojnacka Wójcik, Ewa ^a   Pilc, Andrzej ^a,c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anxiety; Metabotropic glutamate receptors; Neuropeptide Y

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CHLORDIAZEPOXIDE; DIAZEPAM; FLUMAZENIL; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID 5 RECEPTOR ANTAGONIST; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MAZE TEST; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RAT; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY;

AMYGDALA; ANIMALS; MALE; NEUROPEPTIDE Y; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, GABA-A; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 12144289648     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300322     Document Type: Article

References (60)

1. Bennett DA, Amrick CL (1986). 2-Amino-7-phosphonoheptanoic acid (AP7) produces discriminative stimuli and anticonflict effects similar to diazepam. Life Sci 39: 2455-2461.
2. Britton KT, Southerland S, Van Uden E, Kirby D, Rivier J, Koob G (1997). Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl) 132: 6-13.
3. Brodkin J, Busse C, Sukoff SJ, Varney MA (2002). Anxiolytic-like activity of the mGluR5 antagonist MPEP. A comparison with diazepam and buspirone. Pharmacol Biochem Behav 73: 359-366.
4. Capurro D, Huidobro-Toro JP (1999). The involvement of neuropeptide Y Y1 receptors in the blood pressure baroreflex: studies with BIBP 3226 and BIBO 3304. Eur J Pharmacol 376: 251-255.
5. Chojnacka-Wojcik E, Klodzinska A, Pilc A (2001). Glutamate receptor ligands as anxiolytics. Curr Opin Invest Drugs 2: 1112-1119.
6. Chojnacka-Wojcik E, Tatarczynska E, Pilc A (1997). The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur J Pharmacol 319: 153-156.
7. Colmers WF, Bleakman D (1994). Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci 17: 373-379.
8. Conn PJ, Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
9. Corbett R, Dunn RW (1993). Effects of 5,7 dichlorokynurenic acid on conflict, social interaction and plus maze behaviors. Neuropharmacology 32: 461-466.
10. Davis M (1992). The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15: 353-375.
11. Davis M, Rainnie D, Cassell M (1994). Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci 17: 208-214.
12. Dumont Y, Cadieux A, Doods H, Fournier A, Quirion R (2000). Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). Can J Physiol Pharmacol 78: 116-125.
13. Fernandez-Guasti A, Lopez-Rubalcava C (1998). Modification of the anxiolytic action of 5-HT1A compounds by GABA-benzodiazepine agents in rats. Pharmacol Biochem Behav 60: 27-32.
14. Ferris P, Seward E, Dawson GR (2001). Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 15: 76-82.
15. Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhohl K et al (2002). [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 12: 407-409.
16. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I et al (1999). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38: 1493-1503.
17. Gustafson EL, Card JP, Moore RY (1986). Neuropeptide Y localization in the rat amygdaloid complex. J Comp Neurol 251: 349-362.
18. Heilig M, McLeod S, Koob GK, Britton KT (1992). Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41: 61-69.
19. Heilig M, Soderpalm B, Engel JA, Widerlov E (1989). Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 98: 524-529.
20. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998). Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284: 654-660.
21. Kask A, Eller M, Oreland L, Harro J (2000). Neuropeptide Y attenuates the effect of locus coeruleus denervation by DSP-4 treatment on social behaviour in the rat. Neuropeptides 34: 58-61.
22. Kerkerian L, Bosler O, Pelletier G, Nieoullon A (1986). Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci Lett 66: 106-112.
23. Kerkerian L, Salin P, Nieoullon A (1988). Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience 26: 809-817.
24. Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pilc A (1999). Potential anti-anxiety, anti-addictive effects of LY354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38: 1831-1839.
25. Martin LJ, Blackstone CD, Huganir RL, Price DL (1992). Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9: 259-270.
26. Micheli F (2000). Methylphenylethynylpyridine (MPEP) Novartis. Curr Opin Invest Drugs 1: 355-359.
27. Midgley LP, Wagstaff JD, Singh NA, Bush LG, Gibb JW, Hanson GR (1994). Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions. Eur J Pharmacol 251: 191-199.
28. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG et al (1997). Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40: 528-537.
29. O'Leary DM, Movsesyan V, Vicini S, Faden AI (2000). Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 131: 1429-1437.
30. Paxinos G, Watson C (1986). The rat brain in stereotoxic coordinates, 2nd edition. Academic Press inc.: San Diego, California, 92-101.
31. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167.
32. Pellow S, File SE (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24: 525-529.
33. Pilc A, Chojnacka-Wojcik E, Tatarczynska E, Borycz J, Kroczka B (2000) Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats. Amino Acids 19: 81-86.
34. Pilc A, Kdzinska A, Branski P, Nowak G, Palucha S, Szewczyk B et al (2002). Multiple MPEP administrations evoke anxiolytic-and antidepressant-like effects in rats. Neuropharmacology 43: 181.
35. Plaznik A, Palejko W, Nazar M, Jessa M (1994). Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 4: 503-512.
36. Przegalinski E, Tatarczynska E, Chojnacka-Wojcik E (2000). The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology 39: 1858-1864.
37. Przegalinski E, Tatarczynska E, Deren-Wesolek A, Chojnacka-Wojcik E (1996). Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav 54: 73-77.
38. Redrobe JP, Dumont Y, Herzog H, Quirion R (2003). Neuropeptide Y (NPY) Y(2) receptors mediate behaviour in two animal models of anxiety: evidence from Y(2) receptor knockout mice. Behav Brain Res 141: 251-255.
39. Sajdyk TJ, Vandergriff MG, Gehlert DR (1999). Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 368: 143-147.
40. Scatton B (1993). The NMDA receptor complex. Fundam Clin Pharmacol 7: 389-400.
41. Schmidt-Mutter C, Pain L, Sandner G, Gobaille S, Maitre M (1998). The anxiolytic effect of gamma-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. Eur J Pharmacol 342: 21-27.
42. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N (1993). Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 163: 53-57.
43. Smialowska M (1995). An inhibitory dopaminergic regulation of the neuropeptide Y immunoreactivity expression in the rat cerebral cortex neurons. Neuroscience 63: 589-595.
44. Smialowska M, Bajkowska M (1998). Reserpine induces increase in neuropeptide Y immunoreactivity in rat amygdala neurons. Pol J Pharmacol 50: 443-447.
45. Smialowska M, Bajkowska M, Przewlocka B, Maj M, Turchan J, Przewlocki R (1999). Effect of 6-hydroxydopamine on neuropeptide Y and corticotropin- releasing factor expression in rat amygdala. Neuroscience 94: 1125-1132.
46. Smialowska M, Legutko B (1991). Influence of imipramine on neuropeptide Y immunoreactivity in the rat brain. Neuroscience 41: 767-771.
47. Smialowska M, Legutko B (1992). Haloperidol-induced increase in neuropeptide Y immunoreactivity in the locus coeruleus of the rat brain. Neuroscience 47: 351-355.
48. Smialowska M, Szewczyk B, Branski P, Wieronska JM, Palucha A, Bajkowska M et al (2002a). Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 42: 1016-1023.
49. Smialowska M, Wieronska JM, Wedzony K (2002b). A search for colocalization of mglula receptors with CRF or NPY in the rat brain amygdala. Folia Histochem Cytobiol 40: 153-154.
50. Soderpalm A, Blomqvist O, Soderpalm B (1995). The yohimbine-induced anticonflict effect in the rat, Part I. Involvement of noradrenergic, serotonergic and endozepinergic(?) mechanisms. J Neural Transm Gen Sect 100: 175-189.
51. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S et al (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295: 1267-1275.
52. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R et al (2001a). Potential anxiolytic-and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132: 1423-1430.
53. Tatarczynska E, Klodzinska A, Kroczka B, Chojnacka-Wojcik E, Pilc A (2001b). The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl) 158: 94-99.
54. Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R et al (2000). Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA 97: 12852-12857.
55. Trullas R, Jackson B, Skolnick P (1989). Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav 34: 313-316.
56. Vidnyászky Z, Hámori J, Négyessy L, Rüegg D, Knöpfel T, Kuhn R et al (1994). Cellular and subcellular localization of the mGluR5a metabotropic glutamate receptor in rat spinal cord. NeuroReport 6: 209-213.
57. Wieronska JM, Branski P, Palvcha A, Smialowska M (2001a). The effect of competitive and non-competitive NMDA receptor antagonists, ACPCand MK-801 on NPY and CRF-like immunoreactivity in the rat brain amygdala. Neuropeptides 35: 219-226.
58. Wieronska JM, Papp M, Pilc A (2001b). Effects of anxiolytic drugs on some behavioral consequences in olfactory bulbectomized rats. Pol J Pharmacol 53: 517-525.
59. Winslow JT, Insel TR, Trullas R, Skolnick P (1990). Rat pup isolation calls are reduced by functional antagonists of the NMDA receptor complex. Eur J Pharmacol 190: 11-21.
60. Wroblewski JT, Danysz W (1989). Modulation of glutamate receptors: molecular mechanisms and functional implications. Annu Rev Pharmacol Toxicol 29: 441-474.